SEC Form 4 · accession 0001104659-17-003115
MARINUS PHARMACEUTICALS INC · MRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Christopher Michael Cashman
Officer — Chairman and CEO · Director
Period of report
Jan 17, 2017
Accepted (ET)
Jan 19, 2017 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.21 | Jan 17, 2017 | A | 141,400 | A | — | Jan 17, 2027 | Common Stock | 141,400 | 141,400 | D |
| Restricted stockF2,F3,F4 | — | Jan 17, 2017 | A | 60,600 | A | — | — | Common Stock | 60,600 | 60,600 | D |
Explanation of responses
- F1Options to purchase shares of common stock vest in 36 equal monthly installments commencing 1/31/2017.
- F2Each share of restricted stock represents the right to receive, at settlement, one share of common stock.
- F3Shares of restricted stock vest in three equal annual installments of 20,200 on 1/17/18, 1/17/19 and 1/17/20.
- F4Not applicable.